Levobupivacaine (DB01002): A Comprehensive Monograph on its Pharmacology, Clinical Utility, and Safety Profile

Executive Summary

Levobupivacaine is a long-acting, small-molecule local anesthetic belonging to the amino-amide class of drugs. It is the pure S-(-)-enantiomer of bupivacaine, a widely used but more cardiotoxic racemic mixture.[1] The primary role of levobupivacaine is to provide local or regional anesthesia and analgesia for a broad spectrum of surgical procedures, obstetric applications, and for postoperative pain management.[1]

The development of levobupivacaine was a targeted effort to create a safer alternative to racemic bupivacaine. Reports in the late 1970s and 1980s linked bupivacaine to severe, and sometimes fatal, cardiotoxicity, particularly with accidental intravascular injection.[4] Subsequent research revealed that this toxicity was stereoselective, residing predominantly with the R-(+)-enantiomer.[5] Consequently, levobupivacaine was isolated and developed to retain the potent and long-lasting anesthetic properties of its parent compound while significantly reducing the risk of cardiovascular and central nervous system (CNS) toxicity.[2] This improved safety margin represents its principal therapeutic advantage and the core rationale for its clinical use.

The mechanism of action of levobupivacaine is consistent with other local anesthetics: it produces a reversible blockade of nerve impulse propagation by inhibiting voltage-gated sodium channels within the neuronal membrane.[1] By binding to the intracellular aspect of these channels, it prevents the influx of sodium ions necessary for depolarization, thereby increasing the threshold for electrical excitation and halting the transmission of pain signals.[1]

Clinically, levobupivacaine is characterized by its high potency and long duration of action, providing effective anesthesia and analgesia for extended periods.[2] Its efficacy is comparable to that of bupivacaine in most settings.[4] A notable feature is its favorable differential sensory-motor blockade, where it produces a profound sensory block with less intense motor impairment, an attribute that is particularly advantageous in scenarios such as labor analgesia where patient mobility is desirable.[7]

Levobupivacaine has received regulatory approval from major agencies worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and is established in modern anesthetic practice.[2] It is considered a first-line agent for procedures requiring large volumes of local anesthetic or for use in high-risk patient populations where the enhanced safety profile over racemic bupivacaine is of paramount importance.

Chemical Identity and Physicochemical Properties

A thorough understanding of the chemical and physical characteristics of levobupivacaine is fundamental to appreciating its pharmacological behavior, formulation, and clinical application.

Nomenclature and Identifiers

Levobupivacaine is identified by a standardized set of names and codes across various chemical and pharmacological databases, ensuring precision in scientific communication and clinical practice.

• Generic Name: Levobupivacaine [1]
• IUPAC Name: (S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide [2]
• Synonyms: A variety of synonyms are used, reflecting its chemical structure and stereochemistry. These include (S)-bupivacaine, (-)-bupivacaine, L-(-)-bupivacaine, (S)-1-Butyl-2',6'-pipecoloxylidide, and the common trade name Chirocaine.[1]
• DrugBank ID: DB01002 [1]
• CAS Number: The Chemical Abstracts Service (CAS) registry number for the free base is 27262-47-1. The hydrochloride salt, which is used in pharmaceutical formulations, is identified by CAS number 27262-48-2.[2]
• ATC Code: N01BB10, which places it in the therapeutic class of Anesthetics (N), specifically Local Anesthetics (N01B), Amides (N01BB).[2]

Chemical Structure and Stereochemistry

Levobupivacaine's structure and stereoisomerism are the defining features that dictate its unique safety profile compared to its racemic parent compound, bupivacaine.

• Chemical Formula: C18​H28​N2​O [1]
• Molecular Weight: The average molecular mass of the free base is approximately 288.43 g/mol. The monoisotopic mass is 288.220163528 g/mol.[1] The hydrochloride salt has an average molecular weight of 324.9 g/mol.[22]
• Structural Class: Levobupivacaine is classified as an amino-amide local anesthetic and is a member of the n-alkylsubstituted pipecoloxylidide family.[1] Its structure consists of three key components: a lipophilic aromatic head (a 2,6-dimethylphenyl, or xylidide, group), an intermediate amide linkage, and a hydrophilic tertiary amine tail (a butyl-substituted piperidine ring).[5] This amphiphilic structure is essential for its anesthetic activity.
• Stereoisomerism: Bupivacaine is a chiral molecule that exists as a racemic mixture of two enantiomers: the S-(-)-enantiomer and the R-(+)-enantiomer. Levobupivacaine is the pure S-(-)-enantiomer, isolated from this mixture.[1] This stereochemical purity is the critical feature responsible for its improved toxicological profile, as the significant cardiotoxicity of racemic bupivacaine is primarily attributed to the R-(+)-enantiomer.[5]

Physical and Chemical Properties

The physicochemical properties of levobupivacaine, particularly its solubility, pKa, and lipophilicity, directly influence its clinical characteristics, such as onset time, potency, and duration of action.

• Appearance: It is a white to off-white crystalline solid or powder.[15]
• Melting Point: The melting point is in the range of 136–137°C.[15]
• Solubility: The free base is poorly soluble in water but soluble in organic solvents like dimethyl sulfoxide (DMSO) and ethanol.[13] To overcome this, it is formulated as a hydrochloride salt for clinical use, which is freely soluble in water (>100 mg/mL) and forms a sterile, isotonic aqueous solution for injection.[23]
• pKa: The acid dissociation constant (pKa) of levobupivacaine is 8.1, which is identical to that of racemic bupivacaine.[5]
• Partition Coefficient (logP): Various sources report logP values ranging from 3.31 to 4.52, indicating that levobupivacaine is a highly lipid-soluble compound.[16]

The high pKa value has a direct and predictable impact on the drug's onset of action. At a physiological pH of 7.4, the Henderson-Hasselbalch equation demonstrates that a drug with a pKa of 8.1 will exist predominantly in its protonated, ionized (cationic) form. A smaller fraction will remain as the un-ionized, lipid-soluble free base. Local anesthetics must penetrate the lipid-rich nerve sheath and neuronal membrane to reach their site of action on the intracellular side of the sodium channel.[1] This transit is only possible for the un-ionized form.[5] Because only a small proportion of levobupivacaine is in this lipid-soluble state at body pH, its diffusion across the nerve membrane is slow. This slow diffusion is the rate-limiting step for reaching an effective concentration at the target site, which explains the relatively slow onset of anesthesia, typically observed to be 10 to 15 minutes or longer.[2]

Conversely, the drug's high lipid solubility, as indicated by its high logP value, is fundamentally linked to its high potency and long duration of action. High lipophilicity facilitates the partitioning of the drug into the lipid bilayer of the nerve membrane, concentrating it near the sodium channel targets.[28] This high local concentration contributes to its potency. Furthermore, its lipophilicity, combined with its high degree of plasma protein binding (>97%), creates a local tissue depot effect.[2] This slows the rate at which the drug is cleared from the nerve tissue and absorbed into the systemic circulation, thereby prolonging its presence at the site of action and resulting in a long duration of anesthesia that can extend for many hours.[2]

Property	Value	Source(s)
IUPAC Name	(S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide	2
Generic Name	Levobupivacaine	1
Common Synonyms	(S)-bupivacaine, (-)-bupivacaine, Chirocaine	1
DrugBank ID	DB01002	1
CAS Number (Base)	27262-47-1	2
CAS Number (HCl Salt)	27262-48-2	2
ATC Code	N01BB10	2
Chemical Formula	C18​H28​N2​O	1
Molecular Weight (Base)	~288.43 g/mol	1
pKa	8.1	5
logP (Partition Coefficient)	3.31 - 4.52	19
Water Solubility (HCl Salt)	Freely soluble (>100 mg/mL)	26
Structural Class	Amino-amide; n-alkylsubstituted pipecoloxylidide	1

Comprehensive Pharmacological Profile

The pharmacological profile of levobupivacaine is defined by its specific interactions at the molecular level, its resulting effects on nerve physiology and systemic tissues, and its disposition within the body.

Mechanism of Action

Levobupivacaine's primary therapeutic effect—local anesthesia—is achieved through a well-defined molecular mechanism targeting neuronal excitability.

• Primary Target: Voltage-Gated Sodium Channels: The principal mechanism of action for levobupivacaine, like all local anesthetics, is the reversible blockade of nerve impulse generation and conduction.[3] It achieves this by targeting voltage-gated sodium channels, which are critical for the initiation and propagation of action potentials in excitable membranes.[3] The drug binds specifically to a receptor site located on the intracellular portion of the channel's alpha subunit.[1] The sodium channel protein type 10 subunit alpha (Nav1.8), encoded by the SCN10A gene, is a documented molecular target.[16]
• Molecular Action: Upon reaching its intracellular target, levobupivacaine physically obstructs the channel pore. This blockade prevents the large, transient influx of sodium ions that underlies the rapid depolarization phase of an action potential.[1] By inhibiting this sodium flux, levobupivacaine effectively:

1. Increases the threshold for electrical excitation in the nerve, making it more difficult to initiate an action potential.[1]
2. Slows the rate of propagation of the nerve impulse along the axon.[1]
3. Reduces the rate of rise and the overall amplitude of the action potential.[1]

The cumulative effect of these actions is the cessation of signal transmission along the targeted nerve fiber, resulting in localized anesthesia.30

• Use-Dependent Blockade: The interaction between levobupivacaine and the sodium channel is dynamic, a property known as use-dependent or phasic blockade.[5] The drug exhibits a higher affinity for sodium channels that are in the open or inactivated states compared to those in the resting state. Nerves that are firing frequently, such as those actively transmitting nociceptive (pain) signals, have their sodium channels cycling through the open and inactivated states more often. This makes them more susceptible to blockade by levobupivacaine than quiescent nerves, enhancing the drug's efficacy in pain control.

Pharmacodynamics

The pharmacodynamic properties of levobupivacaine describe its effects on the body, from the differential blockade of nerve fibers to its systemic actions and potency.

• Differential Nerve Blockade: A clinically significant pharmacodynamic feature of levobupivacaine is its ability to produce a differential blockade of nerve fibers based on their size and degree of myelination.[1] It more potently blocks the small-diameter, unmyelinated C-fibers and lightly myelinated A-delta fibers, which are responsible for transmitting sensations of pain and temperature.[31] Larger, heavily myelinated A-alpha fibers, which control motor function, are less susceptible to the block.[31] This results in a profound sensory block with a less intense and shorter-lasting motor block, a characteristic that is particularly advantageous in clinical settings like labor analgesia, where pain relief is desired without significantly impairing the patient's ability to move or push.[2]
• Potency and Duration of Action: Levobupivacaine is classified as a high-potency, long-acting local anesthetic.[2] Its potency is considered largely equivalent to that of racemic bupivacaine in clinical practice, although it is approximately 13% less potent on a molar basis.[1] The duration of its effect is dose-dependent and substantial, providing sensory blockade for up to 9 hours following epidural administration and as long as 17 hours after a peripheral nerve block, making it suitable for prolonged surgical procedures and extended postoperative analgesia.[2]
• Vasoconstrictive Properties: A key distinction from its parent compound is its intrinsic vasoactive effect. While racemic bupivacaine is known to cause vasodilation, levobupivacaine exhibits mild vasoconstrictive properties.[2] This vasoconstriction reduces local blood flow at the site of injection. This, in turn, slows the rate of systemic absorption of the drug, prolonging its residence time at the targeted nerve. This effect contributes to its longer duration of action and may also enhance its safety margin by reducing peak plasma concentrations.[2] This property allows levobupivacaine to achieve a long duration of action without the need for co-administered vasoconstrictors like epinephrine, which is beneficial in patients for whom epinephrine is contraindicated. However, this vasoconstrictive activity also raises a theoretical concern regarding its potential to reduce blood flow in highly sensitive vascular beds, such as the uteroplacental circulation, necessitating careful monitoring in obstetric patients.[2]
• Emerging Pharmacodynamic Effects (Anti-tumor Activity): Beyond its anesthetic properties, preclinical research has uncovered potential anti-neoplastic effects. In vitro studies have demonstrated that levobupivacaine can inhibit cell proliferation and induce apoptosis in breast cancer and gastric cancer cell lines.[13] The proposed mechanisms include the suppression of the pro-survival PI3K/Akt/mTOR signaling pathway and the induction of ferroptosis, a form of iron-dependent programmed cell death, via the miR-489-3p/SLC7A11 signaling axis in gastric cancer cells.[13] While these findings are preliminary, they suggest a novel dimension to the drug's pharmacology. The use of regional anesthesia is already associated with improved outcomes in cancer surgery, often attributed to the attenuation of the surgical stress response and reduced opioid consumption. The possibility that the local anesthetic itself possesses direct anti-tumor properties could represent a significant paradigm shift, suggesting that the choice of anesthetic agent might one day be considered a factor in influencing long-term oncologic outcomes.

Pharmacokinetics (Absorption, Distribution, Metabolism, and Excretion)

The pharmacokinetic profile of levobupivacaine describes its journey through the body, which is crucial for understanding its duration of action and potential for systemic toxicity.

• Absorption: The rate and extent of systemic absorption of levobupivacaine are highly dependent on the dose administered and the route of administration, with the vascularity of the injection site being a primary determinant.[1] For instance, absorption is more rapid from highly vascular areas. Following epidural administration, absorption is characteristically biphasic, involving a rapid initial uptake of a fraction of the drug into the circulation, followed by a much slower, prolonged absorption of the remaining drug from the epidural space.[34] Peak plasma concentrations ( Cmax​) are typically observed approximately 30 minutes after an epidural dose.[1] Co-administration with a vasoconstrictor such as epinephrine can slow the rate of absorption, thereby reducing peak plasma levels and potentially lowering the risk of systemic toxicity.[35]
• Distribution: Once in the systemic circulation, levobupivacaine is widely distributed. After intravenous administration, it has a volume of distribution of approximately 67 liters.[1] A key pharmacokinetic feature is its extensive binding to plasma proteins, exceeding 97%.[2] It binds primarily to alpha-1-acid glycoprotein (AAG).[5] This high degree of protein binding means that less than 3% of the drug circulates as the free, unbound form, which is the pharmacologically active and potentially toxic fraction.[5] This dynamic has important clinical implications. Conditions that decrease plasma protein levels, such as in neonates, patients with severe liver disease, or malnutrition, can lead to a higher free fraction of the drug, increasing the risk of toxicity even at standard doses.[34] Conversely, because AAG is an acute-phase reactant that increases in response to surgical stress, its levels rise postoperatively.[37] During a continuous infusion, these rising AAG levels can bind more levobupivacaine, effectively buffering the free drug concentration and providing a dynamic safety margin that may explain the low incidence of toxicity despite accumulating total drug levels.[37]
• Metabolism: Levobupivacaine undergoes extensive hepatic metabolism, with virtually no unchanged drug found in the urine or feces.[1] The metabolism is primarily mediated by the cytochrome P450 (CYP) enzyme system.[5] Two main pathways have been identified:

1. N-dealkylation to its major metabolite, desbutyl-levobupivacaine, is mediated by the CYP3A4 isoform.
2. Hydroxylation to 3-hydroxy-levobupivacaine is mediated by the CYP1A2 isoform. These primary metabolites, which are largely inactive, subsequently undergo further Phase II metabolism, including conjugation with glucuronic acid and sulfate, to form more water-soluble compounds that can be readily excreted.1 A crucial metabolic feature is the lack of stereochemical inversion. In vitro and in vivo studies have confirmed that S-(-)-levobupivacaine is not converted to the more toxic R-(+)-bupivacaine enantiomer, ensuring that its favorable safety profile is maintained throughout its time in the body.[1]

• Excretion: The water-soluble metabolites of levobupivacaine are eliminated from the body primarily through the kidneys. Following intravenous administration, recovery of a radiolabeled dose is nearly complete within 48 hours, with approximately 71% excreted in the urine and 24% in the feces.[1] The elimination half-life of levobupivacaine is relatively short, reported to be between 1.3 and 3.3 hours, reflecting efficient hepatic clearance.[1]

Clinical Applications and Evidence-Based Dosing

The clinical utility of levobupivacaine spans a wide range of anesthetic and analgesic applications, supported by specific dosing guidelines tailored to the procedure, patient population, and desired clinical effect.

Approved Indications and Off-Label Uses

Levobupivacaine is approved by regulatory bodies worldwide for numerous applications in adults and has specific indications in children. Its use also extends to several off-label and investigational areas.

• Approved Indications (Adults and Adolescents ≥12 years):
• Surgical Anesthesia: Levobupivacaine is indicated for producing local or regional anesthesia for both major and minor surgical procedures. For major surgery, it is used for epidural blocks (including for Cesarean section), intrathecal (spinal) blocks, and peripheral nerve blocks. For minor surgery, it is used for local infiltration and peribulbar blocks in ophthalmic surgery.[1]
• Pain Management: It is widely used for the management of acute pain, including postoperative pain, labor pain, and some forms of chronic pain. Administration methods include continuous epidural infusion or single and multiple bolus injections.[1] For enhanced analgesia, particularly in the postoperative setting, it can be administered in combination with epidural opioids (e.g., fentanyl, morphine) or alpha-2 agonists like clonidine.[3]
• Approved Indications (Children):
• The primary approved indication for levobupivacaine in the pediatric population is for infiltration analgesia, specifically for ilioinguinal and iliohypogastric nerve blocks, which are commonly performed for postoperative pain relief after inguinal hernia repair.[1] Labeling varies by region, with some specifying use in children older than 6 months or 12 years.[30] The most consistent and well-established pediatric indication is for these specific peripheral nerve blocks.[45] The evolution of labeling reflects a growing body of evidence supporting its safety and efficacy in children, gradually expanding its formal indications beyond initial, more cautious recommendations.
• Off-Label and Investigational Uses:
• Chronic Pain Conditions: The potential role of levobupivacaine in managing chronic pain is being explored. A clinical trial is investigating its efficacy via local injection for treating pain and disability associated with chronic lateral epicondylitis (tennis elbow), an application outside its standard acute pain indications.[47]
• Specialized Pediatric Analgesia: Beyond its approved use, levobupivacaine is being studied for other pediatric applications. One trial is evaluating its use as a local infiltrate, with or without the adjuvant dexmedetomidine, for managing post-tonsillectomy pain in children—a common and significant clinical challenge.[48]
• Veterinary Anesthesia: Levobupivacaine is used off-label in veterinary medicine, particularly in canine patients, for regional anesthetic techniques such as nerve blocks for dental and oral procedures.[41]
• Expanded Regional Techniques: While intrathecal and peripheral nerve blocks are approved indications, the use of levobupivacaine in a vast array of specific, advanced regional anesthetic techniques is guided more by clinical practice and evidence than by explicit labeling for every possible block, a common scenario for many well-established anesthetics.[49]

Dosage and Administration Guidelines

The safe and effective use of levobupivacaine hinges on adherence to established dosing principles and procedure-specific recommendations.

• Core Principles of Administration:

1. Use the Minimum Effective Dose: The smallest dose and lowest concentration necessary to achieve the desired level of anesthesia or analgesia should always be administered to minimize the risk of systemic toxicity.[3]
2. Incremental Dosing and Aspiration: To prevent accidental intravascular injection, doses should be administered incrementally (fractionated). Before and during the injection of each fraction, careful aspiration should be performed to check for the return of blood or cerebrospinal fluid.[44]
3. Use of a Test Dose: For major conductive blocks like epidural anesthesia, the administration of a small test dose (e.g., 3-5 mL of a rapid-onset local anesthetic, often containing epinephrine) is strongly recommended to detect unintentional intravascular or intrathecal catheter placement before the main dose is given.[44]

• Maximum Recommended Doses:
• The maximum recommended single dose for an adult is typically 150 mg.[45]
• The maximum recommended total dose over a 24-hour period is 400 mg.[45]
• For continuous epidural infusions for postoperative pain, the rate should not exceed 18.75 mg/hour.[45]

The following table summarizes evidence-based dosing regimens for various clinical applications.

Procedure/Block Type	Patient Population	Concentration (mg/mL)	Typical Volume (mL)	Typical Total Dose (mg)	Expected Motor Block
Epidural (Surgical Anesthesia)	Adults	5.0 - 7.5	10 - 20	50 - 150	Moderate to Complete
Epidural (Cesarean Section)	Adults	5.0	15 - 30	75 - 150	Moderate to Complete
Epidural (Labor Analgesia - Bolus)	Adults	2.5	6 - 10	15 - 25	Minimal to Moderate
Epidural (Labor Analgesia - Infusion)	Adults	1.25	4 - 10 mL/hr	5 - 12.5 mg/hr	Minimal to Moderate
Intrathecal (Spinal Anesthesia)	Adults	5.0	3	15	Moderate to Complete
Peripheral Nerve Block	Adults	2.5 - 5.0	1 - 40	2.5 - 150 (max)	Moderate to Complete
Local Infiltration	Adults	2.5	1 - 60	2.5 - 150 (max)	Not Applicable
Ophthalmic (Peribulbar Block)	Adults	7.5	5 - 15	37.5 - 112.5	Moderate to Complete
Ilioinguinal/Iliohypogastric Block	Children	2.5 - 5.0	0.25 - 0.5 mL/kg/side	1.25 mg/kg/side	Not Applicable

Data compiled from.[30]

Use in Special Populations

Dosing must be carefully adjusted in specific patient populations to account for physiological differences that can alter the drug's pharmacokinetics and pharmacodynamics.

• Pediatric Patients: Dosing in children is strictly calculated based on body weight to avoid toxicity. For the approved indication of ilioinguinal/iliohypogastric block, the recommended dose is 1.25 mg/kg per side.[44] For other regional techniques, such as caudal blocks, a maximum single-shot dose of 2.5 mg/kg is generally accepted.[51] Continuous infusion rates are lower, typically 0.2–0.4 mg/kg/h.[51] Neonates and young infants require particular caution and further dose reduction due to their immature hepatic metabolism and lower levels of plasma proteins (specifically AAG), which results in a higher free fraction of the drug and an increased risk of systemic toxicity.[34]
• Geriatric Patients: Elderly, frail, or acutely ill patients should receive reduced doses of levobupivacaine. Age-related declines in cardiovascular, hepatic, and renal function can impair drug clearance and increase susceptibility to adverse effects.[44] Furthermore, elderly patients may exhibit a greater spread of epidural analgesia, necessitating smaller volumes to achieve the desired block height.[2] Dosing should be commensurate with their physical status and comorbidities.
• Obstetric Patients: The use of levobupivacaine in obstetrics requires specific precautions. The 0.75% (7.5 mg/mL) concentration is strictly contraindicated for any obstetric use due to the heightened risk of severe cardiotoxicity in this population.[2] For labor analgesia, lower concentrations such as 0.125% or 0.25% are preferred to provide effective pain relief while minimizing motor block, thereby preserving the patient's ability to push during delivery.[4] For epidural anesthesia for Cesarean section, the maximum recommended dose is 150 mg, and for labor analgesia infusions, the rate should not exceed 12.5 mg/hour.[45] Paracervical block is an absolute contraindication due to the risk of fetal bradycardia.[2]
• Patients with Hepatic Impairment: Levobupivacaine is extensively metabolized by the liver. In patients with severe liver disease (e.g., cirrhosis) or reduced hepatic blood flow, drug metabolism can be significantly impaired, leading to drug accumulation and an increased risk of systemic toxicity. Therefore, levobupivacaine should be used with caution, and dose reduction may be necessary in this population.[30]

Comparative Analysis with Bupivacaine and Ropivacaine

The clinical positioning of levobupivacaine is best understood through a direct comparison with its racemic parent, bupivacaine, and its main contemporary, ropivacaine. The choice among these three long-acting amide local anesthetics is a frequent decision point in clinical practice, driven by considerations of safety, potency, and the specific characteristics of the desired nerve block.

Levobupivacaine vs. Racemic Bupivacaine

The primary distinction between levobupivacaine and racemic bupivacaine lies in their safety profiles, which was the foundational reason for levobupivacaine's development.

• Safety Profile: Levobupivacaine possesses a significantly superior safety margin. The cardiotoxicity of racemic bupivacaine is primarily mediated by its R-(+)-enantiomer, which has a higher affinity for and slower dissociation from cardiac sodium and potassium channels.[5] As the pure S-(-)-enantiomer, levobupivacaine exhibits less affinity for these channels, resulting in a markedly lower risk of inducing life-threatening arrhythmias and myocardial depression.[2] Animal studies and human volunteer trials consistently demonstrate that a higher systemic dose of levobupivacaine is required to produce CNS toxicity (e.g., seizures) and cardiovascular collapse compared to bupivacaine.[5] This makes levobupivacaine a safer choice, particularly in procedures requiring large volumes of anesthetic or in patients with pre-existing cardiac conditions.
• Potency and Efficacy: In clinical settings, levobupivacaine and bupivacaine are considered to have largely equivalent anesthetic efficacy.[4] On a molar basis, levobupivacaine is approximately 13% less potent.[1] Some clinical studies have reported a slightly longer duration of sensory block with levobupivacaine, which may be attributable to its intrinsic vasoconstrictive properties.[4] However, this is not a universal finding, and in certain contexts, particularly at lower doses, some clinicians have observed a faster regression of the block with levobupivacaine, sometimes necessitating higher doses to match the duration of bupivacaine.[58]

Levobupivacaine vs. Ropivacaine

Ropivacaine, another S-enantiomer, was also developed as a safer alternative to bupivacaine. The comparison between levobupivacaine and ropivacaine is more nuanced, focusing on subtle differences in potency and block characteristics.

• Potency: Levobupivacaine is demonstrably more potent than ropivacaine. While the exact potency ratio varies across studies and clinical endpoints, levobupivacaine is generally considered to be 1.3 to 1.5 times more potent than ropivacaine.[28] This means that a smaller mass or volume of levobupivacaine is required to produce an equivalent anesthetic effect.
• Onset and Duration: The onset of action is variable in comparative studies, with some finding a faster onset with ropivacaine and others reporting no significant difference.[31] A more consistent finding is that levobupivacaine provides a significantly longer duration of both sensory analgesia and motor block compared to an equipotent dose of ropivacaine.[31]
• Differential Blockade: Ropivacaine is particularly noted for its greater degree of motor-sensory differentiation. It produces less intense and shorter-lasting motor blockade for a given level of sensory block compared to both bupivacaine and levobupivacaine.[31] This makes ropivacaine a particularly attractive option for ambulatory surgery or labor analgesia, where rapid recovery of motor function is a primary goal.

Clinical Utility in Pediatric Anesthesia

In the pediatric population, the choice between these agents often balances the need for effective analgesia with the desire for rapid recovery and a wide safety margin.

• Comparative studies in children undergoing caudal blocks have shown that while all three agents are effective and hemodynamically stable, they present a distinct trade-off profile.[62] Racemic bupivacaine tends to provide the longest duration of postoperative analgesia but is associated with the most prolonged motor block recovery.[62] Both levobupivacaine and ropivacaine offer a shorter duration of analgesia but with a significantly faster return of motor function, an important advantage in the context of day-care surgery to facilitate earlier ambulation and discharge.[63] Levobupivacaine may offer analgesia comparable to ropivacaine at a lower concentration, reflecting its higher potency.[64]

The selection among these three anesthetics is not a matter of one being universally superior, but rather a clinical decision based on a spectrum of properties. Bupivacaine offers the highest potency and longest duration but carries the highest risk. Ropivacaine sits at the other end, offering the greatest safety margin and motor-sparing effect at the cost of lower potency and shorter duration. Levobupivacaine occupies a valuable intermediate position, providing efficacy and duration nearly equivalent to bupivacaine but with a safety profile that approaches that of ropivacaine. This makes it a versatile and reliable agent for a wide range of applications, especially when a long duration of action is desired but the toxicity risk of bupivacaine is unacceptable.

Characteristic	Bupivacaine (Racemic)	Levobupivacaine	Ropivacaine
Chemical Structure	Racemic mixture (S- and R-enantiomers)	Pure S-(-)-enantiomer	Pure S-(-)-enantiomer (propyl analogue)
Relative Potency	High (+++)	High (++)	Moderate (+)
Onset of Action	Slow (10-20 min)	Slow (10-20 min)	Slow (10-20 min)
Duration of Action (Sensory)	Very Long (+++)	Very Long (+++)	Long (++)
Duration of Action (Motor)	Long (+++)	Long (++)	Moderate (+)
Degree of Motor Block	Dense (+++)	Dense (++)	Less Dense (+)
Intrinsic Vasoactivity	Vasodilation	Mild Vasoconstriction	Vasoconstriction
Cardiotoxicity Risk	High (+++)	Low (+)	Very Low (+)
Neurotoxicity Risk	Moderate (++)	Low (+)	Low (+)
Primary Clinical Advantage	Longest duration, high potency	Favorable safety profile with long duration	Greatest safety margin, significant motor-sparing
Primary Clinical Disadvantage	Highest cardiotoxicity risk	Less motor-sparing than ropivacaine	Less potent, shorter duration than others

Data compiled from.[2]

Safety, Toxicology, and Risk Mitigation

While levobupivacaine was developed for its improved safety profile, it is not devoid of risk. A comprehensive understanding of its potential adverse effects, contraindications, and the management of systemic toxicity is essential for its safe clinical use.

Adverse Effects, Warnings, and Precautions

The adverse effects of levobupivacaine can be categorized as those related to the anesthetic technique and those resulting from systemic drug toxicity.

• Common Adverse Effects: The most frequently reported adverse events are often a physiological consequence of the regional anesthetic technique rather than a direct drug effect. Hypotension, resulting from sympathetic nerve blockade during epidural or spinal anesthesia, is the most common, occurring in up to 31% of patients.[32] Other common effects include nausea, vomiting, postoperative pain, fever, headache, dizziness, and pruritus.[37]
• Local Anesthetic Systemic Toxicity (LAST): This is the most serious and life-threatening complication, typically resulting from accidental intravascular injection or administration of an excessive dose, leading to supratherapeutic plasma concentrations. LAST manifests with a spectrum of CNS and cardiovascular signs and symptoms.
• Central Nervous System (CNS) Toxicity: The CNS is generally more sensitive to local anesthetic toxicity than the cardiovascular system, and symptoms often appear first. Early, prodromal signs include circumoral (perioral) numbness, metallic taste in the mouth, tinnitus, light-headedness, and blurred vision.[2] As plasma levels rise, these can progress to excitatory signs such as restlessness, anxiety, muscle twitching, and ultimately, generalized tonic-clonic seizures. At very high concentrations, the excitatory phase is followed by profound CNS depression, leading to unconsciousness, respiratory depression, and coma.[2]
• Cardiovascular Toxicity: Cardiotoxic effects are a direct result of the drug's blockade of sodium, potassium, and calcium channels in the myocardium and cardiac conduction system.[2] Manifestations include hypotension, bradycardia, conduction abnormalities (e.g., QRS widening, AV block), ventricular arrhythmias (ventricular tachycardia and fibrillation), decreased myocardial contractility, and ultimately, cardiovascular collapse and cardiac arrest.[2] While levobupivacaine is significantly less cardiotoxic than bupivacaine, it can still cause these severe events at toxic concentrations.[10]
• Warnings and Precautions:
• Patient-Related Factors: Special caution is required in patients with pre-existing conditions that may increase their susceptibility to toxicity. This includes patients with impaired cardiovascular function (e.g., severe arrhythmias, heart block), severe hepatic disease (which impairs metabolism and clearance), or severe renal dysfunction.[30] Elderly, debilitated, or acutely ill patients also require careful dose reduction.[44]
• Procedural Safeguards: Safe administration practices are critical. These include avoiding the rapid injection of large volumes, using incremental (fractionated) dosing, and performing frequent aspiration for blood or CSF.[44] The use of levobupivacaine for periods exceeding 24 hours requires close monitoring.[44]
• Methemoglobinemia: Levobupivacaine, like other amide anesthetics, carries a risk of causing methemoglobinemia, a rare but serious condition in which hemoglobin is oxidized to methemoglobin, rendering it unable to transport oxygen. This leads to functional anemia and tissue hypoxia. The risk is elevated in neonates and infants, and in patients receiving concurrent medications known to induce methemoglobinemia.[1]

Contraindications

There are several absolute contraindications for the use of levobupivacaine:

• Known hypersensitivity or allergy to levobupivacaine or any other amide-type local anesthetic.[2]
• Intravenous regional anesthesia (Bier's block), due to the high risk of systemic toxicity if the tourniquet fails.[2]
• Paracervical block in obstetrics, due to the risk of fetal bradycardia and other adverse fetal outcomes.[2]
• Patients with severe hypotension, such as in cases of cardiogenic or hypovolemic shock.[2]
• The 0.75% (7.5 mg/mL) concentration is specifically contraindicated for obstetric anesthesia due to the high risk of cardiotoxicity associated with this concentration in pregnant patients.[2]

Overdose and Management of Local Anesthetic Systemic Toxicity (LAST)

The management of LAST is a medical emergency that requires immediate recognition and a coordinated, protocol-driven response.

• Recognition: Clinicians must maintain a high index of suspicion for LAST following any regional anesthetic injection. The onset is usually rapid (within minutes) but can be delayed. Key signs are the sudden onset of altered mental status, seizures, arrhythmias, or cardiovascular instability.[37]
• Immediate Management Protocol:

1. Stop the Injection: Immediately cease administration of the local anesthetic.
2. Call for Help: Alert nearby staff and activate the institutional LAST response protocol. A dedicated LAST rescue kit containing lipid emulsion and other emergency drugs should be immediately available.
3. Airway Management: The immediate priority is to prevent hypoxia and acidosis, as they potentiate local anesthetic toxicity. Provide 100% oxygen. If the patient's airway or ventilation is compromised, secure the airway with an endotracheal tube without delay.[68]
4. Seizure Suppression: Treat seizures promptly with benzodiazepines (e.g., midazolam 1-2 mg IV, lorazepam 0.1 mg/kg IV). Small, titrated doses of propofol may be used as a second-line agent, but with caution due to its potential to cause hypotension and myocardial depression.[68]

• Specific Antidote: Intravenous Lipid Emulsion (ILE) Therapy:
• ILE therapy is the cornerstone of LAST treatment and should be administered at the first sign of significant toxicity (e.g., seizures, cardiovascular instability).[76]
• Dosing Regimen (20% Lipid Emulsion):
• Initial Bolus: For patients >70 kg, administer a 100 mL bolus intravenously over 2-3 minutes. For patients <70 kg, the bolus is 1.5 mL/kg.[68]
• Continuous Infusion: Immediately follow the bolus with an infusion at a rate of 0.25 mL/kg/minute (or ~15 mL/kg/hour).[78]
• Repeat Bolus: If hemodynamic stability is not restored, the initial bolus can be repeated once or twice, and the infusion rate may be doubled to 0.5 mL/kg/minute.[68]
• Duration and Maximum Dose: The infusion should be continued for at least 10 minutes after cardiovascular stability is achieved. The total cumulative dose should generally not exceed 12 mL/kg.[68]
• Cardiovascular Support (Modified ACLS Protocol):
• If cardiac arrest occurs, standard cardiopulmonary resuscitation (CPR) should be initiated. Resuscitation may need to be prolonged.[68]
• Vasopressors: For hypotension or pulseless electrical activity (PEA), use small, titrated doses of epinephrine (e.g., boluses of ≤1 mcg/kg) to avoid provoking ventricular arrhythmias. Standard large ACLS doses (1 mg) should be avoided.[78]
• Antiarrhythmics: Amiodarone is the preferred agent for ventricular arrhythmias. Local anesthetic antiarrhythmics such as lidocaine or procainamide are contraindicated.[68]
• Contraindicated Medications: Avoid vasopressin, calcium channel blockers, and beta-blockers, as they can worsen myocardial depression and hypotension in the setting of LAST.[68]
• Refractory Cases: For refractory cardiovascular collapse, veno-arterial extracorporeal membrane oxygenation (VA-ECMO) or cardiopulmonary bypass should be considered if available.[78]

Drug-Drug Interactions

The risk of adverse effects from levobupivacaine can be increased by concurrent administration of other drugs. Clinicians must be aware of these potential interactions.

Interacting Drug Class	Example Drugs	Mechanism of Interaction	Clinical Implication/Management
Other Local Anesthetics	Lidocaine, Ropivacaine	Additive toxic effects	Avoid coadministration if possible. If necessary, reduce the dose of each agent and monitor closely for signs of CNS and cardiovascular toxicity.73
CNS Depressants	Benzodiazepines, Opioids, General Anesthetics	Additive CNS depression	Increased risk of sedation and respiratory depression. Monitor respiratory status and level of consciousness closely.1
CYP3A4 Inhibitors	Ketoconazole, Erythromycin, Protease Inhibitors	Inhibition of levobupivacaine metabolism	Increased plasma concentrations of levobupivacaine, leading to a higher risk of systemic toxicity. Use with caution and consider dose reduction.29
CYP1A2 Inhibitors	Methylxanthines (e.g., Theophylline)	Inhibition of levobupivacaine metabolism	May increase plasma concentrations of levobupivacaine. Monitor for toxicity.54
CYP450 Inducers	Rifampin, Phenobarbital, Phenytoin	Induction of levobupivacaine metabolism	Decreased plasma concentrations of levobupivacaine, potentially leading to reduced efficacy or shorter duration of action.29
Drugs Associated with Methemoglobinemia	Nitrates, Nitrites, Sulfonamides, Acetaminophen, Primaquine	Additive risk of inducing methemoglobinemia	Increased risk of clinically significant methemoglobinemia. Monitor for signs of cyanosis and hypoxia. Coadministration requires close supervision.1
Class III Antiarrhythmics	Amiodarone	Additive cardiac effects	Potential for additive toxic effects on cardiac conduction. Use with caution and monitor cardiac function closely.54
Ergot-Type Oxytocic Drugs	Methylergonovine	Synergistic hypertensive effect (when used with epinephrine-containing solutions)	May cause severe, persistent hypertension or cerebrovascular accidents. Avoid concurrent use.30
Nonselective Beta-Blockers	Propranolol, Nadolol	Blocks beta-2 mediated vasodilation, leading to unopposed alpha-1 vasoconstriction (with epinephrine-containing solutions)	May produce severe hypertension and reflex bradycardia. Avoid concurrent use if possible; monitor hemodynamics closely if necessary.73

Data compiled from.[1]

Regulatory and Commercial History

The development, approval, and market trajectory of levobupivacaine provide a compelling case study in pharmaceutical innovation driven by safety concerns, the regulatory pathway for chirally pure drugs, and the pharmacoeconomic factors that influence clinical adoption.

Global Regulatory Status and History

• Development Rationale: The impetus for developing levobupivacaine emerged directly from clinical safety signals associated with its parent compound, racemic bupivacaine, in the late 1970s.[2] Reports of severe and often fatal cardiotoxicity, particularly in the obstetric population, prompted research that identified the R-(+)-enantiomer as the primary toxic component.[5] This discovery created a clear scientific and commercial rationale to develop the S-(-)-enantiomer as a separate drug, with the hypothesis that it would offer a similar anesthetic profile with a significantly improved safety margin.[80] This strategy is a classic example of "chiral switching," where a single, more favorable enantiomer of an existing racemic drug is developed as a new therapeutic entity.
• FDA Approval (United States):
• The New Drug Application (NDA 20997) for Chirocaine (levobupivacaine) was submitted by Purdue Pharma L.P..[11]
• The FDA granted initial approval on August 5, 1999.[11]
• The regulatory review process was extensive, involving 26 clinical trials with over 1,400 patients designed to demonstrate not only efficacy but, crucially, a superior safety profile compared to bupivacaine.[27] A key goal for the sponsor was to justify that the black box warning required for 0.75% bupivacaine in obstetrics was not necessary for levobupivacaine.[80]
• In a significant post-marketing development, the NDA holder voluntarily requested the withdrawal of Chirocaine from the market in May 2004, citing commercial reasons. The withdrawal became effective on April 4, 2005.[11] This event illustrates the full lifecycle of a branded drug: after a period of market exclusivity, commercial pressures from cheaper alternatives (generic bupivacaine) and a competing safer agent (ropivacaine) likely rendered the premium-priced brand less viable.
• Crucially, in May 2023, following a citizen petition, the FDA formally determined that this withdrawal was not for reasons of safety or efficacy.[11] This regulatory finding was pivotal, as it cleared the path for the FDA to approve Abbreviated New Drug Applications (ANDAs) from generic manufacturers, transforming levobupivacaine from a niche branded product into a more widely accessible and affordable generic medication.
• EMA and Other Regions (Europe, Australia):
• Levobupivacaine received approval in Europe concurrently with its US approval. The brand Chirocaine was registered in Sweden, for example, in December 1998.[12]
• It is regulated as a prescription-only medicine (POM or Rx-only) in the European Union and the United Kingdom.[2]
• In Australia, it is approved for anesthesia with a similar safety profile and contraindications as in other major markets.[75]
• Following the patent expiry of the innovator product, generic versions of levobupivacaine have been approved in Europe through the decentralized procedure, with Fresenius Kabi being one prominent example.[83]

International Brand Names and Manufacturers

• Originator Brand: The original and most well-known brand name for levobupivacaine is Chirocaine.[1]
• Originator Companies: The development and marketing of Chirocaine have been associated with several pharmaceutical companies over its lifecycle, including Chiroscience, Darwin Discovery Ltd., AstraZeneca, Abbott Laboratories, and Purdue Pharma.[1] AbbVie is also cited as a marketer.[2]
• Other International Brand Names: Other brand names used in various markets include Novabupi and Levo-anawin.[17]
• Generic Manufacturers: The transition of levobupivacaine to a generic drug has led to a diverse global manufacturing landscape. Numerous companies now produce both the active pharmaceutical ingredient (API) and the finished injectable solution. Prominent generic manufacturers and suppliers include Altan Pharma, Fresenius Kabi, and a large number of companies based in China and India, such as Senova Technology, Shandong Chenghui Shuangda Pharmaceutical, and Gonane Pharma.[45]

Expert Synthesis and Clinical Recommendations

Levobupivacaine represents a significant and rational advancement in the field of local anesthesia. Its development as the pure S-(-)-enantiomer of bupivacaine successfully addressed the primary safety concern of its predecessor—severe cardiotoxicity—without sacrificing the desirable characteristics of high potency and long duration of action. Its established clinical profile positions it as a cornerstone of modern regional anesthesia and pain management.

Levobupivacaine's Place in Modern Anesthesia

Levobupivacaine is not merely an alternative to bupivacaine but a refinement. Its principal value is its enhanced safety profile, which makes it the preferred long-acting local anesthetic in clinical situations where the risk of local anesthetic systemic toxicity (LAST) is elevated. While its efficacy is comparable to bupivacaine, its wider therapeutic index provides a crucial safety margin that can be lifesaving in the event of an accidental intravascular injection or overdose.

Key Clinical Scenarios for Preferential Use

Based on its pharmacological profile, levobupivacaine is the agent of choice in several specific clinical contexts:

• Procedures Requiring Large Volumes or High Doses: For major peripheral nerve blocks (e.g., brachial plexus, lumbar plexus, sciatic nerve blocks) and epidural anesthesia for major surgery, which often require large volumes of local anesthetic, the superior safety profile of levobupivacaine makes it a more prudent choice than racemic bupivacaine.
• Continuous Nerve Block Catheters: For postoperative pain management via continuous epidural or peripheral nerve block infusions, where the drug is administered over an extended period (up to 24 hours or more), the risk of drug accumulation exists. Levobupivacaine's lower systemic toxicity makes it a safer option for these techniques.
• Obstetric Anesthesia: In labor epidural analgesia, levobupivacaine's ability to provide profound sensory analgesia with less motor blockade is a distinct advantage, facilitating maternal effort during delivery. Its enhanced safety is also paramount in this sensitive patient population.
• High-Risk Patients: For patients with pre-existing cardiovascular disease, severe hepatic impairment, or for elderly and frail individuals, the reduced cardiotoxic and neurotoxic potential of levobupivacaine offers a critical safety advantage over bupivacaine.

Considerations for Choosing Between Levobupivacaine and Ropivacaine

The choice between levobupivacaine and ropivacaine is more nuanced and should be guided by the specific goals of the anesthetic.

• Choose Levobupivacaine when the primary objective is to maximize the duration of analgesia. Its higher potency and longer intrinsic duration of action make it superior for prolonged surgeries and for providing extended postoperative pain relief.[31]
• Choose Ropivacaine when the primary objective is to minimize motor blockade and facilitate rapid recovery. Its greater motor-sparing properties and shorter duration of action make it ideal for ambulatory surgery, where early ambulation and discharge are key goals.[31]

Critical Safety Mandates

The improved safety profile of levobupivacaine does not eliminate risk. Safe clinical practice requires unwavering adherence to fundamental safety principles:

1. Dose Appropriately: Always use the minimum effective dose and concentration. Strictly adhere to weight-based dosing in pediatric patients and reduce doses in elderly or high-risk individuals.
2. Administer with Care: Employ meticulous technique, including incremental injections and frequent aspiration, to minimize the risk of intravascular injection.
3. Be Prepared for Toxicity: Every location where regional anesthesia is performed must have immediate access to a LAST rescue kit, including 20% lipid emulsion. All clinical staff must be trained in the recognition of LAST and the updated, modified resuscitation protocol.

Future Directions

The clinical story of levobupivacaine may not be complete. Emerging preclinical evidence of its direct anti-tumor effects opens an exciting new avenue of research.[13] Future clinical trials in onco-anesthesia are warranted to investigate whether the choice of local anesthetic can influence cancer recurrence or metastasis, potentially adding a disease-modifying role to its established analgesic and anesthetic functions. Furthermore, its application in managing specific chronic pain syndromes continues to be an area of active investigation.[47] Levobupivacaine remains a vital tool in the anesthesiologist's armamentarium, offering a reliable combination of efficacy, long duration, and a safety profile that has set a higher standard for regional anesthetic practice.

Works cited

1. Levobupivacaine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 23, 2025, https://go.drugbank.com/drugs/DB01002
2. Levobupivacaine - Wikipedia, accessed July 23, 2025, https://en.wikipedia.org/wiki/Levobupivacaine
3. Drug Criteria & Outcomes: Levobupivacaine (Chirocaine) Formulary Evaluation, accessed July 23, 2025, https://www.clinician.com/articles/119412-drug-criteria-outcomes-levobupivacaine-chirocaine-formulary-evaluation
4. Levobupivacaine - PubMed, accessed July 23, 2025, https://pubmed.ncbi.nlm.nih.gov/9777312/
5. levobupivacaine, accessed July 23, 2025, https://resources.wfsahq.org/wp-content/uploads/uia-14-LEVOBUPIVACAINE.pdf
6. Cardiac and CNS toxicity of levobupivacaine: strengths of evidence for advantage over bupivacaine - PubMed, accessed July 23, 2025, https://pubmed.ncbi.nlm.nih.gov/11945112/
7. Levobupivacaine: A review of its pharmacology and use as a local anesthetic | Request PDF, accessed July 23, 2025, https://www.researchgate.net/publication/12539585_Levobupivacaine_A_review_of_its_pharmacology_and_use_as_a_local_anesthetic
8. What is the mechanism of Levobupivacaine? - Patsnap Synapse, accessed July 23, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-levobupivacaine
9. go.drugbank.com, accessed July 23, 2025, https://go.drugbank.com/drugs/DB01002#:~:text=Local%20anesthetics%20such%20as%20Levobupivacaine,rise%20of%20the%20action%20potential.
10. Clinical Pharmacokinetics and Pharmacodynamics of Levobupivacaine - Sci-Hub, accessed July 23, 2025, https://sci-hub.se/downloads/2020-02-09/b5/10.1007@s40262-020-00868-0.pdf
11. Determination That Chirocaine (Levobupivacaine) Injection, 2.5 Milligrams (Base)/Milliliter, 10 Milliliter and 30 Milliliter Vials, 5 Milligrams (Base)/Milliliter, 10 Milliliter and 30 Milliliter Vials and 7.5 Milligrams (Base)/Milliliter, 10 Milliliter and 30 Milliliter Vials, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness - Federal Register, accessed July 23, 2025, https://www.federalregister.gov/documents/2023/05/25/2023-11162/determination-that-chirocaine-levobupivacaine-injection-25-milligrams-basemilliliter-10-milliliter
12. Public Assessment Report Scientific discussion Levobupivacaine Molteni 0.625 mg/ml and 1.25 mg/ml, solution for infusion - Geneesmiddeleninformatiebank, accessed July 23, 2025, https://www.geneesmiddeleninformatiebank.nl/pars/h115878.pdf
13. Levobupivacaine free base | CAS# 27262-47-1 - MedKoo Biosciences, accessed July 23, 2025, https://www.medkoo.com/products/8664
14. Levobupivacaine | C18H28N2O - ChemSpider, accessed July 23, 2025, https://www.chemspider.com/Chemical-Structure.83289.html
15. Levobupivacaine | 27262-47-1 - ChemicalBook, accessed July 23, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB52130881.htm
16. Levobupivacaine (T3D2955) - T3DB, accessed July 23, 2025, https://www.t3db.ca/toxins/T3D2955
17. Levobupivacaine | C18H28N2O | CID 92253 - PubChem, accessed July 23, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/92253
18. Levobupivacaine - brand name list from Drugs.com, accessed July 23, 2025, https://www.drugs.com/ingredient/levobupivacaine.html
19. Compound: LEVOBUPIVACAINE (CHEMBL1201193) - ChEMBL - EMBL-EBI, accessed July 23, 2025, https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1201193
20. Levobupivacaine | C18H28N2O | CID 92253 - PubChem, accessed July 23, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Levobupivacaine
21. Levobupivacaine - Chemical Details, accessed July 23, 2025, https://comptox.epa.gov/dashboard/chemical/details/DTXSID8048496
22. 20997 Chirocaine Injection, 2.5, 5.0, 7.5 mg per mL Final Print Label - accessdata.fda.gov, accessed July 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20997_chirocaine_prntlbl.pdf
23. Levobupivacaine HCl | CAS#27262-48-2 - MedKoo Biosciences, accessed July 23, 2025, https://www.medkoo.com/products/8326
24. go.drugbank.com, accessed July 23, 2025, https://go.drugbank.com/drugs/DB01002#:~:text=Levobupivacaine%20is%20an%20amino%2Damide,family%20of%20n%2Dalkylsubstituted%20pipecoloxylidide.
25. (-)-Bupivacaine - CAS RN: 27262-47-1 - Tokyo Chemical Industry, accessed July 23, 2025, https://www.tcichemicals.com/IN/en/p/B6449
26. Levobupivacaine hydrochloride | DrugBank Online, accessed July 23, 2025, https://go.drugbank.com/salts/DBSALT000834
27. 20997 Chirocaine Injection, 2.5, 5.0, 7.5 mg per mL Clinical Pharmacology Biopharmaceutics Review - accessdata.fda.gov, accessed July 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20997_CHIROCAINE_biopharmr.pdf
28. Efficacy of Levobupivacaine in Regional Anaesthesia - A Narrative Review, accessed July 23, 2025, https://www.jmedicalcasereports.org/article_html.php?did=15400&issueno=0
29. What is Levobupivacaine used for? - Patsnap Synapse, accessed July 23, 2025, https://synapse.patsnap.com/article/what-is-levobupivacaine-used-for
30. Levobupivacaine - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Hepatic Dose | Drug Index | Pediatric Oncall, accessed July 23, 2025, https://www.pediatriconcall.com/drugs/levobupivacaine/705
31. Levobupivacaine or ropivacaine: A randomised double blind controlled trial using equipotent doses in spinal anaesthesia | Colombian Journal of Anesthesiology - Elsevier, accessed July 23, 2025, https://www.elsevier.es/es-revista-revista-colombiana-anestesiologia-341-articulo-levobupivacaine-or-ropivacaine-a-randomised-S225620871600016X
32. Levobupivacaine: a review of its pharmacology and use as a local anaesthetic - PubMed, accessed July 23, 2025, https://pubmed.ncbi.nlm.nih.gov/10776835/
33. Levobupivacaine ((S)-(-)-Bupivacaine) | Sodium Channels Blocker/Ferroptosis Inducer, accessed July 23, 2025, https://www.medchemexpress.com/levobupivacaine.html
34. Clinical profile of levobupivacaine in regional anesthesia: A systematic review - PMC, accessed July 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3819850/
35. Clinical Pharmacokinetics and Pharmacodynamics of Levobupivacaine | Request PDF, accessed July 23, 2025, https://www.researchgate.net/publication/339127150_Clinical_Pharmacokinetics_and_Pharmacodynamics_of_Levobupivacaine
36. The systemic absorption and disposition of levobupivacaine 0.5% after epidural administration in surgical patients: a stable-isotope study | European Journal of Anaesthesiology - Cambridge University Press, accessed July 23, 2025, https://www.cambridge.org/core/journals/european-journal-of-anaesthesiology/article/systemic-absorption-and-disposition-of-levobupivacaine-05-after-epidural-administration-in-surgical-patients-a-stableisotope-study/A2328EBC8C59A6F16939216D81AAE677
37. Update on local anesthetics: focus on levobupivacaine - PMC - PubMed Central, accessed July 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2504073/
38. Efficacy and safety of 0.5% levobupivacaine versus 0.5% bupivacaine for peribulbar anesthesia - PMC, accessed July 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3665566/
39. A study of the dosage and duration for levobupivacaine infusion by the caudal-epidural route in infants aged 3-6 months - PubMed, accessed July 23, 2025, https://pubmed.ncbi.nlm.nih.gov/30447167/
40. PDR 57, accessed July 23, 2025, https://www.pmda.go.jp/drugs/2008/P200800015/73011900_22000AMX01587_B102_1.pdf
41. The pharmacokinetics of levobupivacaine 0.5% after infraorbital or inferior alveolar block in anesthetized dogs - Frontiers, accessed July 23, 2025, https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2022.1055231/full
42. Absorption pharmacokinetics of levobupivacaine. | Download Table - ResearchGate, accessed July 23, 2025, https://www.researchgate.net/figure/Absorption-pharmacokinetics-of-levobupivacaine_tbl1_263656367
43. Chirocaine; SOLUTION FOR INJECTION & CONCENTRATED SOLUTION FOR INFUSION, accessed July 23, 2025, https://www.nps.org.au/medicine-finder/chirocaine-solution-for-infusion
44. CHIROCAINE - Levobupivacaine Injection - PRODUCT NAME, accessed July 23, 2025, https://registrasiobat.pom.go.id/files/assesment-reports/obat_baru/Chirocaine%20Larutan%20injeksi%205%20mg,mL_Levobupivakain_DKI1450200343A1_2017.pdf
45. Levobupivacaine 5 mg/ml solution for injection/infusion - Summary of Product Characteristics (SmPC) - (emc) | 13644, accessed July 23, 2025, https://www.medicines.org.uk/emc/product/13644/smpc
46. Summary of Product Characteristics - HPRA, accessed July 23, 2025, https://assets.hpra.ie/products/Human/30233/Licence_PA2059-009-003_18052021115309.pdf
47. Study Details | Levobupivacaine Versus Liposomal Bupivacaine (Exparel®) for Treatment of Pain and Disability in Lateral Epicondylitis | ClinicalTrials.gov, accessed July 23, 2025, https://clinicaltrials.gov/study/NCT04382144
48. Study Details | Levobupivacaine vs Levobupivacaine + Dexmedetomidine Infiltration for Post-tonsillectomy Analgesia and Laryngospasm in Pediatric Patients | ClinicalTrials.gov, accessed July 23, 2025, https://clinicaltrials.gov/study/NCT04113720
49. Local Anesthetics Are Off-Label For Spinals - RK.MD, accessed July 23, 2025, https://rk.md/2016/local-anesthetics-off-label-spinals/
50. Bupivacaine Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed July 23, 2025, https://www.drugs.com/dosage/bupivacaine.html
51. Regional Anesthesia in Pediatric Patients: General Considerations - NYSORA, accessed July 23, 2025, https://www.nysora.com/topics/sub-specialties/pediatric-anesthesia/regional-anesthesia-pediatric-patients-general-considerations/
52. Levobupivacaine caudal anesthesia in children: a randomized double-blind comparison with bupivacaine - PubMed, accessed July 23, 2025, https://pubmed.ncbi.nlm.nih.gov/16879518/
53. Safe dose of levobupivacaine (Chirocaine®) in caudal analgesia in children | BJA: British Journal of Anaesthesia | Oxford Academic, accessed July 23, 2025, https://academic.oup.com/bja/article/90/3/400/252153
54. Part II Summary of Product Characteristics - HPRA, accessed July 23, 2025, https://assets.hpra.ie/products/Human/13770/LicenseSPC_PA0038-071-001_16022008021431.pdf
55. highlights of prescribing information - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed July 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/018053s061lbl.pdf
56. Central nervous system toxicity following the administration of levobupivacaine for lumbar plexus block: A report of two cases - PubMed, accessed July 23, 2025, https://pubmed.ncbi.nlm.nih.gov/12677626/
57. Drug Criteria & Outcomes: Levobupivacaine (Chirocaine) Formulary Evaluation, accessed July 23, 2025, https://www.reliasmedia.com/articles/119412-drug-criteria-outcomes-levobupivacaine-chirocaine-formulary-evaluation
58. Doses and effects of levobupivacaine and bupivacaine for spinal anaesthesia | BJA - Oxford Academic, accessed July 23, 2025, https://academic.oup.com/bja/article/113/3/521/275934
59. Levobupivacaine versus ropivacaine in patients undergoing lower abdominal surgeries - IP Innovative Publication, accessed July 23, 2025, https://pdf.ipinnovative.com/pdf/19213
60. Levobupivacaine or ropivacaine: A randomised double blind controlled trial using equipotent doses in spinal anaesthesia | Colombian Journal of Anesthesiology, accessed July 23, 2025, https://www.revcolanest.com.co/index.php/rca/article/view/453
61. Levobupivacaine versus Ropivacaine: A Comparative Study of the Analgesic and Hemodynamic Spectrum, accessed July 23, 2025, https://www.ijss-sn.com/uploads/2/0/1/5/20153321/ijss_apr_oa39.pdf
62. A Comparative Study of 0.25% Levobupivacaine, 0.25% Ropivacaine, and 0.25% Bupivacaine in Paediatric Single Shot Caudal Block - PMC, accessed July 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6234439/
63. A comparison between Levobupivacaine, Ropivacaine & Bupivacaine in caudal anaesthesia in children undergoi - Indian Journal Of Basic And Applied Medical Research, accessed July 23, 2025, https://www.ijbamr.com/assets/images/issues/pdf/September%202015%20654-661.pdf.pdf
64. Levobupivacaine for regional blockades in orthopedics and traumatology in children: recent evidence and future directions, accessed July 23, 2025, https://journals.eco-vector.com/turner/article/view/10343
65. Pediatric Epidural and Spinal Anesthesia and Analgesia - NYSORA, accessed July 23, 2025, https://www.nysora.com/topics/sub-specialties/pediatric-anesthesia/pediatric-epidural-spinal-anesthesia-analgesia/
66. Full article: Update on local anesthetics: focus on levobupivacaine - Taylor & Francis Online, accessed July 23, 2025, https://www.tandfonline.com/doi/full/10.2147/tcrm.s1433
67. Levobupivacaine 1.25 mg/ml solution for infusion, accessed July 23, 2025, https://www.medicines.org.uk/emc/files/pil.13641.pdf
68. Clinical Practice Guidelines : Local anaesthetic poisoning - The Royal Children's Hospital, accessed July 23, 2025, https://www.rch.org.au/clinicalguide/guideline_index/Local_anaesthetic_poisoning/
69. Levobupivacaine: Indications, Side Effects, Warnings - Drugs.com, accessed July 23, 2025, https://www.drugs.com/cdi/levobupivacaine.html
70. Full article: A review of local anesthetic cardiotoxicity and treatment with lipid emulsion, accessed July 23, 2025, https://www.tandfonline.com/doi/full/10.2147/lra.s8814
71. Local Anesthetic Systemic Toxicity - NYSORA, accessed July 23, 2025, https://www.nysora.com/topics/complications/local-anesthetic-systemic-toxicity/
72. Levobupivacaine and primaquine Interactions - Drugs.com, accessed July 23, 2025, https://www.drugs.com/drug-interactions/levobupivacaine-with-primaquine-1452-0-1939-0.html
73. bupivacaine hydrochloride injection, USP Drug Interactions | Pfizer Medical - US, accessed July 23, 2025, https://www.pfizermedical.com/bupivacaine-hydrochloride/drug-interactions
74. Bupivacaine (injection route) - Side effects & uses - Mayo Clinic, accessed July 23, 2025, https://www.mayoclinic.org/drugs-supplements/bupivacaine-injection-route/description/drg-20406723
75. Levobupivacaine hydrochloride - Australian Prescriber - Therapeutic Guidelines, accessed July 23, 2025, https://australianprescriber.tg.org.au/articles/levobupivacaine-hydrochloride-1.html
76. Local Anesthetic Systemic Toxicity: Symptoms & Treatment - Cleveland Clinic, accessed July 23, 2025, https://my.clevelandclinic.org/health/diseases/local-anesthetic-systemic-toxicity-last
77. Local anesthetic toxicity: acute and chronic management - PMC - PubMed Central, accessed July 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5667269/
78. Local Anesthetic Systemic Toxicity (LAST) - EMCrit Project, accessed July 23, 2025, https://emcrit.org/ibcc/last/
79. Levobupivacaine 0.625 mg/ml solution for infusion - HPRA, accessed July 23, 2025, https://assets.hpra.ie/products/Human/30231/b258b91f-7658-4485-90b3-3b022da256e6.pdf
80. 20997 Chirocaine Injection, 2.5, 5.0, 7.5 mg per mL Medical Review Part 1 - accessdata.fda.gov, accessed July 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20997_CHIROCAINE_medr_P1.pdf
81. Drug Approval Package:Chirocaine (Levobupivacaine) NDA# 20997 - accessdata.fda.gov, accessed July 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20997_Chirocaine.cfm
82. Federal Register/Vol. 88, No. 101/Thursday, May 25, 2023/Notices - GovInfo, accessed July 23, 2025, https://www.govinfo.gov/content/pkg/FR-2023-05-25/pdf/2023-11165.pdf
83. Public Assessment Report Scientific discussion Levobupivacaïne Fresenius Kabi 0.625 mg/ml and 1.25 mg/ml, solution for infusion - Geneesmiddeleninformatiebank, accessed July 23, 2025, https://www.geneesmiddeleninformatiebank.nl/pars/h113450.pdf
84. Suppliers for Levobupivacaine 75mg/10ml solution for injection ampoules - dm+d browser, accessed July 23, 2025, https://dmd-browser.nhsbsa.nhs.uk/vmp/view/5547/suppliers?ref=
85. Anesthesia; Spinal Unknown Status Phase 3 Trials for Levobupivacaine (DB01002), accessed July 23, 2025, https://go.drugbank.com/indications/DBCOND0081580/clinical_trials/DB01002?phase=3&status=unknown_status
86. Study Details | Comparison of Levobupivacaine, Ropivacaine and Bupivacaine in Epidural Anaesthesia | ClinicalTrials.gov, accessed July 23, 2025, https://www.clinicaltrials.gov/study/NCT02513433?term=AREA%5BConditionSearch%5D(Insensitivity%20to%20pain,%20congenital)&rank=1
87. Levobupivacaine API Suppliers - Find All GMP Manufacturers - Pharmaoffer.com, accessed July 23, 2025, https://pharmaoffer.com/api-excipient-supplier/local-anesthetics/levobupivacaine
88. Levobupivacaine hydrochloride manufacturers and suppliers - ChemicalBook, accessed July 23, 2025, https://m.chemicalbook.com/Manufacturers/Levobupivacaine-hydrochloride.htm